Combination Therapy with Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis Induced Clinical Remission in a Crohn's Disease Patient with the Loss of Response to Scheduled Adalimumab Maintenance Therapy: A Case Report

被引：8
|
作者：
Ozeki, Keiji [1 ]
Tanida, Satoshi [1 ]
Mizushima, Takashi [2 ]
Mizoshita, Tsutomu [1 ]
Tsukamoto, Hironobu [1 ]
Hirata, Yoshikazu [1 ]
Murakami, Kenji [1 ]
Shimura, Takaya [1 ]
Kataoka, Hiromi [1 ]
Kamiya, Takeshi [1 ]
Joh, Takashi [1 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan
[2] Gifu Prefectural Tajimi Hosp, Gifu, Japan
来源：
INTERNAL MEDICINE | 2012年 / 51卷 / 06期
关键词：
refractory Crohn's disease; adalimumab; intensive granulocyte/monocyte adsorptive apheresis; anti-adalimumab antibody; clinical remission; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; NECROSIS-FACTOR; TRIAL; MULTICENTER; INFECTION;
D O I：
10.2169/internalmedicine.51.6801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.
引用
收藏
页码：595 / 599
页数：5
相关论文
共 50 条
  • [31] THE INTRA-PATIENT VARIABILITY OF ADALIMUMAB CLEARANCE DURING AN INTENSIVE SAMPLING STUDY OF CROHN'S DISEASE PATIENTS RECEIVING MAINTENANCE THERAPY
    Strong, April
    Han, Patricia Aragon
    Sparrow, Miles
    Dervieux, Thierry
    Ward, Mark
    GASTROENTEROLOGY, 2024, 166 (05) : S832 - S833
  • [32] The intra-patient variability of adalimumab clearance during an intensive sampling study of Crohn's disease patients receiving maintenance therapy
    Strong, A.
    Aragon-Han, P.
    Sparrow, M.
    Dervieux, T.
    Ward, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1744 - I1744
  • [33] Opportunistic skin infections with Mycobacterium marinum under adalimumab therapy in a patient with Crohn's disease - a case report.
    Kump, Patrizia
    Hoegenauer, Christoph
    Wenzl, Heimo
    Hinterleitner, Thomas
    Petritsch, Wolfgang
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (17-18) : A14 - A14
  • [34] Addition of an Immunomodulator as a Rescue Therapy for Loss of Response to Adalimumab Dose Escalation in Patients With Crohn's Disease
    Papamichael, Konstantinos
    Karatzas, Pantelis
    Mantzaris, Gerassimos J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (07): : 589 - 590
  • [35] Adalimumab-induced palmoplantar pustular psoriasis in a patient with Crohn's disease with good response to phototherapy: Case report
    de Andrade, Jhessica
    Pereira, Luiza
    Pizani, Natassia
    Teixeira, Marcelo
    Missio, Dandara
    Pantaleao, Luciana
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 29 - 30
  • [36] Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
    Peyrin-Biroulet, L.
    Laclotte, C.
    Bigard, M. -A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (06) : 675 - 680
  • [37] Adalimumab Maintenance Therapy Improves Patient-Reported Outcomes in Patients with Moderate Crohn's Disease: Subanalysis of CHARM
    Loftus, Edward
    Yang, Mei
    Mulani, Parvez
    Chao, Jingdong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S449 - S450
  • [38] Failure of response to combination therapy of adalimumab and infliximab in a recalcitrant patient of severe psoriasis and major thalassemia: A case report
    Goldust, Mohamad
    Rokni, Ghasem Rahmatpour
    Gupta, Mrinal
    Lotti, Torello
    Bathaei, Marzieh
    CLINICAL CASE REPORTS, 2020, 8 (03): : 550 - 552
  • [39] Improved mucosal healing during scheduled adalimumab maintenance therapy in patients with Crohn's disease initiated following surgical resection of active lesions
    Yamada, A.
    Iwashita, H.
    Sasaki, T.
    Katsumata, M.
    Miyamura, M.
    Kikuchi, H.
    Arai, T.
    Iwasa, R.
    Furukawa, R.
    Sono, K.
    Osamura, A.
    Nakamura, K.
    Aoki, H.
    Yoshimatsu, Y.
    Tsuda, Y.
    Takeuchi, K.
    Takada, N.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S358 - S359
  • [40] Remission and clinical response to adalimumab at 4 weeks in patients with active luminal Crohn's disease who had lost response to or were intolerant of infliximab therapy
    Hinojosa, Joaquin
    Garcia, S.
    Esteve, M.
    Garcia, V.
    Martinez, P.
    Obrador, A.
    Gassull, M. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S455 - S456
12345